Acadian Asset Management
INZY

Acadian Asset Management’s Inozyme Pharma INZY Stock Holding History

Acadian Asset Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110,376
Closed -$100K – 1739
2025
Q1 		$100K Buy
+110,376
New +$153K ﹤0.01% 1353
2023
Q3 		– Sell
-57,468
Closed -$319K – 1736
2023
Q2 		$319K Buy
+57,468
New +$340K ﹤0.01% 1169
2022
Q1 		– Sell
-3,676
Closed -$25K – 1711
2021
Q4 		$25K Hold
3,676
– – ﹤0.01% 1581
2021
Q3 		$42K Buy
+3,676
New +$57.3K ﹤0.01% 1575

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Acadian Asset Management's INZY Position: Q2 2025 in Review

Acadian Asset Management sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 110,376 shares — an estimated $100K sold.

Acadian Asset Management first reported a position in INZY in Q3 2021 and held it in 4 quarters. The position peaked at $319K in Q2 2023. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Acadian Asset Management reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Acadian Asset Management sold 110,376 Inozyme Pharma shares in Q2 2025, an estimated $100K.
  • Acadian Asset Management first reported a position in Inozyme Pharma in Q3 2021 and held it in 4 quarters.
  • Acadian Asset Management's Inozyme Pharma position peaked at $319K in Q2 2023.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.